🟠 Moderate Evidence
A new all-oral drug combination for older patients with acute myeloid leukemia (AML) has demonstrated effectiveness comparable to current intravenous treatments, potentially eliminating the need for monthly hospital visits. The ASCERTAIN V clinical trial showed that combining two oral medications—decitabine-cedazuridine and venetoclax—achieved strong response rates in elderly AML patients who typically struggle with intensive treatment regimens.
Key takeaways
- All-oral AML treatment combination shows effectiveness comparable to IV therapy in Phase I/II trial
- Older patients could avoid monthly hospital visits for intravenous treatments
- Trial led by major US cancer centers demonstrates strong response rates and survival outcomes
Study at a Glance
| Source | ASCERTAIN V Trial |
| Study type | Phase I/Phase II Clinical Trial |
| Sample size | Older AML patients |
| Population | Elderly patients with acute myeloid leukemia |
| Country | International (US-led) |
AML Treatment Burden Comparison
Current IV therapy vs. new oral combination for older patients
Source: ASCERTAIN V Trial, 2026 | Georgian Medical Journal News
Breakthrough for Elderly Cancer Patients
The ASCERTAIN V trial, led by researchers at Weill Cornell Medicine, NewYork-Presbyterian, Yale University and MD Anderson Cancer Center, represents a significant advance in AML treatment for older adults. Current standard therapy requires patients to travel repeatedly to medical facilities for intravenous drug administration, creating substantial burden for elderly individuals who may have mobility limitations or live far from treatment centers.
The oral combination therapy consists of decitabine-cedazuridine, which delivers the same active ingredient as IV decitabine but in pill form, paired with venetoclax, an established oral cancer medication. This approach could transform care delivery for a vulnerable patient population that often struggles with the physical demands of frequent medical visits.
Clinical Trial Results Show Promise
The international Phase I/Phase II trial demonstrated that the all-oral regimen achieved response rates and survival outcomes comparable to current intravenous treatments, according to the research team. AML primarily affects older adults, with a median age at diagnosis of approximately 68 years, making treatment accessibility a critical concern for this population.
Patients in the study took the oral medication combination at home, eliminating the need for repeated IV infusions that typically require several hours at a medical facility. The National Cancer Institute notes that AML treatment burden is particularly challenging for elderly patients, who may have multiple comorbidities and limited support systems.
Implications for Cancer Care Delivery
The oral treatment approach addresses longstanding challenges in AML care, particularly for patients in rural areas or those with limited transportation options. Traditional IV-based hypomethylating agent therapy requires regular medical facility visits, creating barriers to consistent treatment adherence among elderly patients.
Researchers from the multi-institutional team noted that the convenience factor could significantly improve quality of life while maintaining therapeutic effectiveness. The study builds on previous research showing that oral formulations of cancer drugs can achieve similar bioavailability to IV preparations when properly formulated.
The all-oral drug combination for older AML patients demonstrated effectiveness comparable to current IV treatments while eliminating monthly hospital visits
— ASCERTAIN V Trial investigators, Multi-institutional research team (Clinical trial results, 2026)
What this means
Frequently asked questions
How effective is the new oral AML treatment compared to IV therapy?
The ASCERTAIN V trial showed that the oral combination achieved response rates and survival outcomes comparable to current intravenous treatments. The two-pill regimen of decitabine-cedazuridine and venetoclax demonstrated strong clinical effectiveness in older patients.
Which patients would be eligible for this oral treatment?
The treatment was studied specifically in older patients with acute myeloid leukemia, who typically face challenges with intensive treatment regimens. Final eligibility criteria will depend on FDA approval and clinical guidelines.
When might this oral treatment become available to patients?
The treatment is currently in clinical trials, with the ASCERTAIN V study providing Phase I/II evidence. Availability will depend on completion of further studies and regulatory approval processes.
The success of oral AML therapy in elderly patients could herald a broader shift toward home-based cancer treatment, particularly for populations where treatment burden significantly impacts quality of life. As healthcare systems increasingly focus on patient-centered care delivery, convenient oral formulations that maintain therapeutic effectiveness represent an important advance in oncology practice.
Source: FDA-approved oral AML therapy could let older patients avoid monthly infusion visits
Was this article helpful?
Related Coverage
